Literature DB >> 9858327

Race and serum prostate-specific antigen levels: current status and future directions.

I Abdalla1, P Ray, S Vijayakumar.   

Abstract

Prostate cancer (PC) is a serious public health problem in the United States, especially in African-American men (AAs). AAs have higher incidence and mortality rates and present with higher stage and grade of PC than other racial/ethnic groups. Given the importance of serum prostate-specific antigen level (PSA) as a screening tool for PC and its prognostic value among patients with PC, exploring the relationship between PSA and race has gained enormous interest lately. The number of studies addressing such relationships has increased tremendously over the past few years. Most of these studies indicate a higher PSA in AAs than whites in men with or without PC even after adjustment for patients' age and prostate volume (in men without PC) and for PC grade and stage (in men with PC). The etiology of higher PSA levels in AAs is not completely understood and might be secondary to biological, environmental/socioeconomic reasons, or both. Studying serum PSA dynamics among AAs may help in elucidating the epidemiological features of PC in AAs.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9858327

Source DB:  PubMed          Journal:  Semin Urol Oncol        ISSN: 1081-0943


  3 in total

1.  Prostate-specific antigen and androgens in African-American and white normal subjects and prostate cancer patients.

Authors:  S O Asbell; K C Raimane; A T Montesano; K L Zeitzer; M D Asbell; S Vijayakumar
Journal:  J Natl Med Assoc       Date:  2000-09       Impact factor: 1.798

Review 2.  Do African-American men need separate prostate cancer screening guidelines?

Authors:  Divya Shenoy; Satyaseelan Packianathan; Allen M Chen; Srinivasan Vijayakumar
Journal:  BMC Urol       Date:  2016-05-10       Impact factor: 2.264

3.  Clinical Implications of Nadir Serum Prostate-Specific Antigen Levels After Transurethral Enucleation of the Prostate.

Authors:  Yung-Ting Cheng; Jian-Hua Hong; Yu-Chuan Lu; Yi-Kai Chang; Shih-Chun Hung; Kuo-Kang Feng; Shih-Ping Liu; Po-Ming Chow; Hong-Chiang Chang; Chung-Hsin Chen; Yeong-Shiau Pu
Journal:  Front Oncol       Date:  2022-07-15       Impact factor: 5.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.